{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:10:56Z","timestamp":1775743856540,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s10147-023-02292-3","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T10:05:48Z","timestamp":1673085948000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-9527","authenticated-orcid":false,"given":"Akifumi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,7]]},"reference":[{"key":"2292_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","volume":"149","author":"EH Baldini","year":"2015","unstructured":"Baldini EH, Richards WG, Gill RR et al (2015) Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 149:1374\u20131381","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2292_CR2","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.athoracsur.2019.11.048","volume":"109","author":"A Nakamura","year":"2020","unstructured":"Nakamura A, Takuwa T, Hashimoto M et al (2020) Clinical outcomes with recurrence after pleurectomy\/decortication for malignant pleural mesothelioma. Ann Thorac Surg 109:1537\u20131543","journal-title":"Ann Thorac Surg"},{"key":"2292_CR3","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/jjco\/hyaa069","volume":"50","author":"A Nakamura","year":"2020","unstructured":"Nakamura A, Kondo N, Nakamichi T et al (2020) Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma. Jpn J Clin Oncol 50:920\u2013925","journal-title":"Jpn J Clin Oncol"},{"key":"2292_CR4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J et al (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial, et al. Lancet 387:1405\u20131414","journal-title":"Lancet"},{"key":"2292_CR5","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, KijimaAoe T et al (2019) Clinical efficacy and safety of nivolumab: results of a multicenter open-label, single-arm, Japanese phase ii study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 25:5485\u20135492","journal-title":"Clin Cancer Res"},{"key":"2292_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicenter, randomised, open-label, phase 3 trial. Lancet 397:375\u2013386","journal-title":"Lancet"},{"key":"2292_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R et al (2022) First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 33:488\u2013499","journal-title":"Ann Oncol"},{"key":"2292_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10147-020-01780-0","volume":"26","author":"A Nakamura","year":"2021","unstructured":"Nakamura A, Hashimoto M, Kodama H et al (2021) Clinicopathological features of radiological early malignant pleural mesothelioma with no apparent tumor or pleural thickening. Int J Clin Oncol 26:95\u2013103","journal-title":"Int J Clin Oncol"},{"key":"2292_CR9","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1245\/s10434-020-09275-y","volume":"28","author":"A Nakamura","year":"2021","unstructured":"Nakamura A, Kondo N, Nakamichi T et al (2021) Complications and predictive factors for air leak > 10 days with neoadjuvant chemotherapy followed by pleurectomy\/decortication for malignant pleural mesothelioma. Ann Surg Oncol 28:3057\u20133065","journal-title":"Ann Surg Oncol"},{"key":"2292_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1053\/j.semtcvs.2021.02.003","volume":"33","author":"A Nakamura","year":"2021","unstructured":"Nakamura A, Hashimoto M, Matsumoto S et al (2021) Outcomes of conversion to extrapleural pneumonectomy from pleurectomy\/decortication for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 33:873\u2013881","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"2292_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257\u2013260","journal-title":"Ann Oncol"},{"key":"2292_CR12","unstructured":"National Cancer Institute. Maryland: Common Terminology Criteria for Adverse Events, version 5.0 (CTCAEv5.0). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed Oct 15 2022"},{"key":"2292_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jtho.2021.07.029","volume":"17","author":"P Baas","year":"2022","unstructured":"Baas P (2022) Nivolumab plus ipilimumab should be the standard of care for first-line unresectable epithelioid mesothelioma. J Thorac Oncol 17:30\u201333","journal-title":"J Thorac Oncol"},{"key":"2292_CR14","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.2147\/CMAR.S224791","volume":"12","author":"M Tsoli","year":"2020","unstructured":"Tsoli M, Kaltsas G, Angelousi A et al (2020) Managing ipilimumab-induced hypophysitis: challenges and current therapeutic strategies. Cancer Manag Res 12:9551\u20139561","journal-title":"Cancer Manag Res"},{"key":"2292_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/14737140.2022.2102482","volume":"22","author":"C Travert","year":"2022","unstructured":"Travert C, Tomasini P, Greillier L (2022) Nivolumab plus ipilimumab in malignant pleural mesothelioma. Expert Rev Anticancer Ther 22:815\u2013822","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02292-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02292-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02292-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T06:09:29Z","timestamp":1678082969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02292-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,7]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2292"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02292-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,7]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takashi Kijima reports receiving speakers bureau honoraria and research funding from Ono Pharmaceutical. Seiki Hasegawa reports endowed department (The Department of Thoracic Oncology, Hyogo Medical University.) from Ono pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}